ProCE Banner Series

Precision in Early-Stage NSCLC Care: Community Workshop on the Optimal Integration of Biomarker-Driven Therapy

Join us for this live 1-hour workshop to learn about the latest recommendations in the management of patients with early-stage NSCLC including biomarker testing and the use of targeted therapies and immunotherapy as neoadjuvant, adjuvant, and perioperative treatments.

  AAPA
  | ACPE
  | AMA
  | AMA
  | ANCC
Who Should Attend

September 28: This program is intended for nurses and other healthcare professionals involved in the diagnosis and management of patients with early-stage non-small cell lung cancer.

September 29: This program is intended for community oncologists, nurses, pharmacists and other healthcare professionals involved in the diagnosis and management of patients with early-stage non-small cell lung cancer.

All Events

Precision in Early-Stage NSCLC Care: Community Workshop on the Optimal Integration of Biomarker-Driven Therapy

Past Events

September

28

2024

3:00 PM - 4:00 PM Pacific Time (PT)

In-person

Private Event | Host Group CA, Los Angeles, California

September

29

2024

9:20 AM - 10:20 AM Central Time (CT)

Virtual

CCO Simulcast | Host Group IL, Winfield, Illinois

Faculty

ProCE Banner Faculty
Nikka Berkowitz, AGACNP-BC, OCN

Nurse Practitioner
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Center
Los Angeles, California

ProCE Banner Faculty
Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of community oncologists regarding the optimal medical and therapeutic management of patients with early-stage non-small cell lung cancer.

Target Audience
September 28: This program is intended for nurses and other healthcare professionals involved in the diagnosis and management of patients with early-stage non-small cell lung cancer.

September 29: This program is intended for community oncologists, nurses, pharmacists and other healthcare professionals involved in the diagnosis and management of patients with early-stage non-small cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate the latest molecular and biomarker testing guidance for the identification of oncogenic drivers in patients with early-stage NSCLC

  • Determine the most appropriate perioperative treatment strategy that incorporates patient-specific factors and the results obtained from biomarker testing

  • Determine if individual patients with resectable early-stage NSCLC who are candidates for enrollment in an ongoing investigational clinical trial based on the presence of an ALK fusion, and counsel patients on the investigational therapies targeting ALK

Accreditation

September 28th event

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


September 29th event

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-218-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Merck Sharp & Dohme LLC.